Hikal’s Q4 profit remained sharply lower year-on-year, falling 71% from Rs. 50.2 crore in Q4 FY25 as the company absorbed regulatory pressures and strategic accounting adjustments
On a full-year basis, revenue from operations for FY26 grew 18.9 percent year-on-year to Rs 827.87 crore compared to Rs 696.48 crore in FY25
For the full year, standalone gross revenue crossed Rs. 1,700 crore
The company highlighted continued demand strength and pricing resilience despite global disruptions
Net profit stood at Rs. 921 crore for the quarter, while Europe revenues surged 30.2% YoY to Rs. 2,795 crore
Eris Lifesciences posts sharp profit surge in FY26 driven by strong diabetes portfolio growth
US formulations grew 11% to Rs. 564 crore as Alembic enters US branded pharmaceuticals market with launch of Pivya
The 38% adjusted EBITDA margin of base business has been supported by robust growth in the CDMO segment
Backed by Semaglutide launches, the company reported 47% quarter-on-quarter revenue growth in Q4 FY26, with EBITDA expanding more than fivefold
The CDMO segment saw a 22% decline in Q4 due to a strong base in the prior year
Subscribe To Our Newsletter & Stay Updated
